This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. PYRGF, NNVC, TAOX, IBIO, ETHZ, NBY, AEON, MTNB, OBSV, and NRBOShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include PyroGenesis Canada (PYRGF), NanoViricides (NNVC), Synaptogenix (TAOX), iBio (IBIO), Flag Ship Acquisition (ETHZ), NovaBay Pharmaceuticals (NBY), AEON Biopharma (AEON), Matinas Biopharma (MTNB), ObsEva (OBSV), and NeuroBo Pharmaceuticals (NRBO). Gemphire Therapeutics vs. Its Competitors PyroGenesis Canada NanoViricides Synaptogenix iBio Flag Ship Acquisition NovaBay Pharmaceuticals AEON Biopharma Matinas Biopharma ObsEva NeuroBo Pharmaceuticals Gemphire Therapeutics (NASDAQ:GEMP) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Is GEMP or PYRGF more profitable? Gemphire Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemphire TherapeuticsN/A -419.70% -173.05% PyroGenesis Canada -115.14%N/A -60.81% Does the media favor GEMP or PYRGF? In the previous week, Gemphire Therapeutics' average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score. Company Overall Sentiment Gemphire Therapeutics Neutral PyroGenesis Canada Neutral Do insiders & institutionals believe in GEMP or PYRGF? 17.5% of Gemphire Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 22.7% of Gemphire Therapeutics shares are held by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, GEMP or PYRGF? Gemphire Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Which has higher valuation and earnings, GEMP or PYRGF? PyroGenesis Canada has higher revenue and earnings than Gemphire Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemphire TherapeuticsN/AN/A-$23.64MN/AN/APyroGenesis Canada$9.14M3.86-$21.12M-$0.03-6.26 SummaryPyroGenesis Canada beats Gemphire Therapeutics on 5 of the 8 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.31M$840.62M$5.80B$10.16BDividend YieldN/A4.84%5.72%4.60%P/E RatioN/A1.1475.2426.40Price / SalesN/A26.51513.38175.37Price / CashN/A19.5625.8129.91Price / Book2.786.6613.606.28Net Income-$23.64M-$4.13M$3.29B$270.38M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$1.50+115.5%N/A-80.7%$22.31MN/A0.009High Trading VolumePYRGFPyroGenesis CanadaN/A$0.18-6.0%N/A-68.7%$35.11M$9.14M-2.9390Gap DownNNVCNanoViricides0.2202 of 5 stars$1.46+1.4%N/A-9.9%$23.47MN/A-2.0320TAOXSynaptogenix0.0708 of 5 stars$6.24-0.5%N/AN/A$21.86MN/A-0.314IBIOiBio1.6872 of 5 stars$0.83-2.6%$5.00+500.4%-53.6%$16.37M$375K-0.48100Short Interest ↑ETHZFlag Ship AcquisitionN/A$2.44flatN/AN/A$14.74MN/A0.007News CoverageNBYNovaBay Pharmaceuticals0.4021 of 5 stars$2.30-14.8%$0.85-63.0%+477.0%$13.40M$9.78M-0.0430Gap DownAEONAEON Biopharma3.1662 of 5 stars$0.75+3.2%$360.00+47,996.2%-98.5%$8.72MN/A4.165News CoverageShort Interest ↓MTNBMatinas Biopharma0.0807 of 5 stars$1.64-1.8%N/AN/A$8.34MN/A-0.3430Negative NewsShort Interest ↑OBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050NRBONeuroBo PharmaceuticalsN/A$0.69+0.0%N/A-80.7%$5.95MN/A0.0010Gap Up Related Companies and Tools Related Companies PyroGenesis Canada Competitors NanoViricides Competitors Synaptogenix Competitors iBio Competitors Flag Ship Acquisition Competitors NovaBay Pharmaceuticals Competitors AEON Biopharma Competitors Matinas Biopharma Competitors ObsEva Competitors NeuroBo Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | SponsoredThe Obscure Korean War Act That Created a $5.39 Billion Passive Income StreamAn obscure Korean War law has just been enacted by the U.S. government... Allowing it to take a heavy hand ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GEMP Stock Alerts